Stock Analysis
- United States
- /
- Machinery
- /
- NasdaqCM:NEPH
Nephros Third Quarter 2024 Earnings: Beats Expectations
Nephros (NASDAQ:NEPH) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$3.52m (down 6.0% from 3Q 2023).
- Net income: US$183.0k (up from US$182.0k loss in 3Q 2023).
- Profit margin: 5.2% (up from net loss in 3Q 2023). The move to profitability was driven by lower expenses.
- EPS: US$0.017 (up from US$0.017 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Nephros Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Machinery industry in the US.
Performance of the American Machinery industry.
The company's shares are up 10% from a week ago.
Risk Analysis
We should say that we've discovered 1 warning sign for Nephros that you should be aware of before investing here.
Valuation is complex, but we're here to simplify it.
Discover if Nephros might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:NEPH
Nephros
A commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States.